{"id":335666,"date":"2025-10-29T00:00:00","date_gmt":"2025-10-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0005-2024-biopharma-parkinsons-disease-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-03-31T10:24:36","modified_gmt":"2026-03-31T10:24:36","slug":"dlsfcg0005-2026-biopharma-parkinsons-disease-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0005-2026-biopharma-parkinsons-disease-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Parkinson&#8217;s Disease &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>Several new brands have recently entered the competitive Parkinson\u2019s disease (PD) therapy market, including AbbVie\u2019s Vyalev \/ Produodopa \/ Scyova (foslevodopa \/ foscarbidopa subcutaneous pump), Amneal\u2019s Crexont (levodopa \/ carbidopa ER), and Supernus\u2019s Onapgo (apomorphine subcutaneous pump), and several more are poised to launch within three years (e.g., Mitsubishi Tanabe \/ NeuroDerm\u2019s ND0612, AbbVie\u2019s tavapadon). Although clinical and commercial opportunity persists in PD, the market has proven challenging for some new entrants. As developers seek to establish a niche for their products, the treatment algorithm will become more complex. While new brands can drive market value, intense competition and patient and payer cost sensitivity in a generic drug market make for a challenging launch environment. With generic alternatives available in all PD drug classes, new brands that lack clinical differentiation will have difficulty competing. Meanwhile, potentially disruptive disease-modifying therapies (DMTs) are filling in the PD pipeline. A thorough grasp of current and future PD market dynamics is crucial for both new and established players vying for a share of this increasingly competitive landscape.<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What will be the clinical and commercial impact of newly launched and emerging levodopa reformulations (i.e., Vyalev \/ Produodopa \/ Scyova, ND0612, and Crexont)?<\/li>\n<li>Where will AbbVie\u2019s dopamine receptor agonist tavapadon fit into the treatment algorithm for PD?<\/li>\n<li>How do neurologists view the clinical prospects for adjunctive therapies for motor fluctuations, dyskinesia, and dementia?<\/li>\n<li>Which putative DMTs are most promising?<\/li>\n<li>Which unmet needs remain for other novel therapies targeting motor symptoms in PD?<\/li>\n<\/ul>\n<p><strong>Markets covered: <\/strong>United States, France, Germany, Italy, Spain, United Kingdom, Japan.<\/p>\n<p><strong>Primary research: <\/strong>Country-specific interviews with thought-leading neurologists; survey data collected for this and other Clarivate research<\/p>\n<p><strong>Epidemiology: <\/strong>Diagnosed and drug-treated prevalent cases of <abbr title=\"Parkinson's disease\">PD<\/abbr> by country.<\/p>\n<p><strong>Drug treatments: <\/strong>Coverage of key current and late-phase emerging therapies<\/p>\n<p>F<strong>orecast: <\/strong>10-year, annualized, drug-level sales and patient share of key PD therapies through 2034, segmented by brands \/ generics and epidemiological subpopulations<\/p>\n<p><b>Product description<\/b><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul>\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-335666","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-neurology","biopharma-therapy-areas-parkinsons-disease","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/335666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":6,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/335666\/revisions"}],"predecessor-version":[{"id":575304,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/335666\/revisions\/575304"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=335666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}